Navigation Links
Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
Date:10/21/2009

PRINCETON, N.J., Oct. 21 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has signed a new Biopharmaceutical Development and Manufacturing Agreement with an undisclosed client. According to the agreement, Laureate will develop the process to manufacture a unique Fc Fusion Protein and produce this product under cGMP conditions for use in clinical trials. Terms of the manufacturing agreement were not disclosed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

"This project is a great fit with the experience that we have developed over the past few years working with fusion proteins," said Robert J. Broeze, Ph. D., President & CEO of Laureate Pharma. "We have had great success working with these unique protein products and are delighted to have the opportunity to help advance this product into the clinic."

"We are seeing a strong trend in the biopharmaceutical industry to develop fusion protein products with unique properties," commented Dan Leone, Vice President, Business Development of Laureate Pharma. "Along with monoclonal antibodies, manufacturing fusion proteins has become one of Laureate's core competencies."

About Laureate Pharma

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, NJ. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact Dan Leone, Vice President, Business Development at 609-919-3300, or info@laureatepharma.com or visit www.laureatepharma.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Robert Broeze | https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=84360

SOURCE Laureate Pharma, Inc.


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University
2. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
3. NASCSA Receives $200,000 Grant From Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
4. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
8. ISTA Pharmaceuticals to Present at 2009 BIOCOM Investor Conference
9. University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales
10. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
11. Four Pharmaceutical Companies Pay $124 Million for Submission of False Claims to Medicaid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... F ast access to ... at the point of need   ... products and services, has launched a ClinicalKey mobile app that ... device. Elsevier designed the mobile app to allow users to select access ... Android and iOS formats for mobile phone and ...
(Date:2/11/2016)... Inc., spurred by a major "team investment" by Bruce Montgomery , one of this area,s ... according to CEO Leen Kawas , PhD. ... ... ... Kawas said the round was intended to ...
(Date:2/11/2016)... 11, 2016  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ... made at the 38th annual John A. Boswick ... which is being held February 14-18, 2016 in ... latest advancements in wound healing, burn care, and infection ... Australian-New Zealand Burns Association, Academy of Physicians in Wound ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... ... As part of their 2015 end of year funding strategy, Colleen’s Dream ... $10,000 to University of Chicago to support ovarian cancer research being conducted by Dr. ... to support a promising young investigator from Dr. Lengyel’s lab at the University of ...
(Date:2/10/2016)... ... February 10, 2016 , ... Sherly ... for a series of therapeutic sessions to help Los Angeles-area actors cope with ... their lives. The series, known as “Mindfulness for Actors and Artists,” has been ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
(Date:2/10/2016)... ... 10, 2016 , ... As part of its ongoing series of aquatic therapy ... webinar features a dynamic expert and thoughtful presentation to give attendees a better sense ... Both events are free to attend, but registration is required. , Rehabilitation ...
(Date:2/10/2016)... ... 10, 2016 , ... Compliancy Group LLC is pleased to ... throughout the country. The Guard was specifically designed to handle each element required ... regulatory updates, and compliance coaching. , In addition to meeting the compliance needs ...
Breaking Medicine News(10 mins):